EUVIMEDEUVIMED entdecken
Crossref

Efficacy and Safety Study of Different Doses of Linezolid in Combination with Bedaquiline in the Treatment of Drug-Resistant Pulmonary Tuberculosis

Xin Wang, Dongpeng Geng, Xiaoling Wu, Zhen Guo, Congling Ma, Xiaonan Ma, Xiaomin Hao, Panyun Xiao

Chemotherapy · 08.04.2026 · 1-9

DOI: 10.1159/000551380 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Chemotherapy, online erschienen am 08.04.2026. Verfasst von Xin Wang und 7 weiteren Autor:innen. Beteiligte Einrichtung: The First Department of Internal Medicine, Shaanxi Provincial Tuberculosis Prevention and Control Hospital, Xi'an, China. Hauptthemen laut MEDLINE: Linezolid, Diarylquinolines, Tuberculosis, Multidrug-Resistant, Antitubercular Agents. Die Arbeit nennt 18 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Drug-resistant tuberculosis presents a major global health challenge due to limited therapeutic options and significant toxicity of traditional regimens. Linezolid, a core Group A drug per WHO guidelines, demonstrates high efficacy but its optimal dosing is debated due to dose-dependent adverse effects. This study aimed to evaluate the efficacy and safety of different initial doses of linezolid combined with bedaquiline for treating drug-resistant pulmonary tuberculosis.

Methods

This retrospective study analyzed patients with drug-resistant tuberculosis treated with bedaquiline and linezolid in China from June 2019–June 2022. The data originated from medical records. Adverse drug reactions were categorized using the Common Terminology Criteria for Adverse Events (v5.0). Three groups were formed based on the initial linezolid dose: 1,200 mg/day (high-dose, n = 99), 600 mg/day (low-dose, n = 121), and 0 mg/day (control, n = 50). Clinical data, epidemiological characteristics, treatment outcomes, adverse events, and prognoses of these groups were compared and analyzed statistically.

Results

Our research scrutinized the effects of different initial doses of linezolid and bedaquiline on drug-resistant tuberculosis. No significant differences were noted between high-dose and low-dose groups in 6 months for sputum smear negativity, cavitary closure time, or time for lesion resorption and reduction. However, a higher incidence of adverse events was observed in the high-dose group (47.47%) compared to the low-dose group (29.75%), with myelosuppression, peripheral neuritis, and optic neuritis being predominant. Notably, the proportion of patients requiring dose adjustment due to adverse events was significantly higher in the high-dose group (74.47%) than in the low-dose group (50%, p = 0.021).

Conclusions

Initial daily linezolid dose of 600 mg and 1,200 mg in combination with bedaquiline yields equivalent efficacy for drug-resistant pulmonary tuberculosis. The lower dose demonstrates improved tolerability. For the said therapy, we advocate a primary recommendation of a daily linezolid dose of 600 mg.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LinezolidDiarylquinolinesTuberculosis, Multidrug-ResistantAntitubercular AgentsTuberculosis, PulmonaryHumansRetrospective StudiesFemaleMaleAdultMiddle AgedDrug Therapy, CombinationTreatment OutcomeDose-Response Relationship, Drug

Stichwörter der Autor:innen

BedaquilineDifferent doseDrug-resistant pulmonary tuberculosisEfficacyLinezolid

Substanzen

LinezolidDiarylquinolinesbedaquilineAntitubercular Agents

Autor:innen und Institutionen

  • The First Department of Internal Medicine, Shaanxi Provincial Tuberculosis Prevention and Control Hospital, Xi'an, China.
  • Department of Tuberculosis, The Third People's Hospital of Linfen City, Shanxi Province, Linfen, China.
  • The Second Department of Internal Medicine, Shaanxi Provincial Tuberculosis Prevention and Control Hospital, Xi'an, China.
  • The First Department of Internal Medicine, Shaanxi Provincial Tuberculosis Prevention and Control Hospital, Xi'an, China, xiaopanyun234@163.com.

Zitieren

APA

Wang, X., Geng, D., Wu, X., Guo, Z., Ma, C., Ma, X., Hao, X., & Xiao, P. (2026). Efficacy and Safety Study of Different Doses of Linezolid in Combination with Bedaquiline in the Treatment of Drug-Resistant Pulmonary Tuberculosis. Chemotherapy, 1-9. https://doi.org/10.1159/000551380

Vancouver

Wang X, Geng D, Wu X, Guo Z, Ma C, Ma X, et al. Efficacy and Safety Study of Different Doses of Linezolid in Combination with Bedaquiline in the Treatment of Drug-Resistant Pulmonary Tuberculosis. Chemotherapy. 2026:1-9. doi:10.1159/000551380

BibTeX
@article{Wang2026,
  author = {Wang, Xin and Geng, Dongpeng and Wu, Xiaoling and Guo, Zhen and Ma, Congling and Ma, Xiaonan and Hao, Xiaomin and Xiao, Panyun},
  title = {Efficacy and Safety Study of Different Doses of Linezolid in Combination with Bedaquiline in the Treatment of Drug-Resistant Pulmonary Tuberculosis},
  journal = {Chemotherapy},
  year = {2026},
  pages = {1--9},
  doi = {10.1159/000551380}
}
Kostenlos starten →